First Human Trial Injects Mitochondria Into the Eye to Treat Vision Loss
A 26‑year‑old woman who suffered severe vision loss after a delayed brain bleed received a pioneering treatment in which mitochondria extracted from her thigh muscle were injected into the vitreous fluid of both eyes. The procedure, reported in a preprint by neuroscientist David Putrino of the Icahn School of Medicine at Mount Sinai and posted to Research Square, produced no serious adverse events and showed early signs of functional improvement, though it did not restore full vision.
Key Takeaways
- First human case of intra‑ocular mitochondrial injection.
- Procedure was safe with no serious adverse events or immune reaction.
- Patient’s pupils and visual cortex showed temporary functional responses.
- Vision acuity remained at light perception; no lasting restoration.
- Researchers plan repeated injections and FDA protocol development.
| Metric | Value | Why it matters |
|---|---|---|
| Patient age | 26 years | Indicates a young patient with potentially more resilient cells. |
| Source institution | Icahn School of Medicine at Mount Sinai | Provides institutional credibility. |
| Procedure | Autologous mitochondria injected into vitreous fluid | Reduces risk of immune rejection. |
| Safety outcome | No serious adverse events | Supports feasibility of further trials. |
What Are Mitochondria and Why They Matter to Vision
Mitochondria are the microscopic powerhouses that convert food and oxygen into usable energy for cells. Retinal ganglion cells, which carry visual signals from the retina to the brain, have some of the highest energy demands in the central nervous system. When blood and oxygen are cut off, damaged mitochondria can trigger a cascade that kills these cells.
Animal studies have shown that transplanted mitochondria can be taken up by retinal cells and help retinal ganglion cells survive after injury.
The Patient’s Journey: From Brain Bleed to Vision Loss
The woman suffered a severe brain bleed and was not brought to hospital until roughly 18 hours later. Emergency surgery saved her life, but the prolonged deprivation of blood and oxygen to her optic nerves left her almost completely blind in both eyes. By eight weeks post‑bleed, her optic nerves showed visible atrophy, and by three months her profound visual impairment had not improved.
Imaging revealed that the retinal nerve‑fiber and ganglion‑cell layers had thinned but had not disappeared. Brain activity tests suggested that some visual information was still reaching the visual cortex, hinting that a subset of retinal ganglion cells remained viable.
The First Human Mitochondrial Eye Injection
To minimize immune risk, doctors harvested a biopsy from the patient’s thigh muscle and processed it to extract tens of millions of mitochondria. These fresh mitochondria were then injected into the jelly‑like fluid inside each eye.
Within days of the injections, the patient’s pupils began to show normal responses to light, a change that had never been observed in the 71 days of pre‑treatment testing.
Early Signs of Functional Improvement
Three separate brain recordings at 3, 44, and 45 days after treatment revealed organized responses in the visual cortex, indicating that visual signals were being processed. However, the patient’s visual acuity remained at the level of light perception, and the pupillary responses were temporary—normal responses in the left eye ceased by day 11, and the right eye’s responses faded by day 39.
Because this was a single case without a control group, the authors caution that the observed changes cannot be definitively attributed to the mitochondrial transplant. No direct evidence confirmed that the injected mitochondria entered retinal ganglion cells.
Limitations and Next Steps
The study’s limited scope means causation remains unproven. Researchers suggest that repeated doses of healthy mitochondria might be necessary to sustain any benefit. Putrino has stated that the team is working with the FDA to develop a protocol for serial mitochondrial injections.
Future investigations will need to confirm mitochondrial uptake by retinal cells and determine whether repeated treatments can produce lasting visual improvement.
Why It Matters
This case demonstrates that injecting autologous mitochondria into the eye is technically feasible and safe in humans. If subsequent trials confirm efficacy, mitochondrial transplantation could become a novel therapeutic avenue for retinal diseases where energy failure contributes to cell death, such as glaucoma or optic neuropathies.
Frequently Asked Questions
What exactly were the mitochondria injected into?
The mitochondria were delivered into the vitreous fluid, the clear gel that fills the space between the lens and retina in each eye.
Did the treatment restore the patient’s vision?
No. The patient’s visual acuity remained at light perception, and the functional improvements observed were temporary.
How many mitochondria were used in the injection?
Doctors extracted tens of millions of mitochondria from a thigh muscle biopsy before injecting them.
What are the next steps for this research?
Researchers plan to develop a protocol for repeated mitochondrial injections and are collaborating with the FDA to design larger, controlled studies.
Is there a risk of an immune reaction?
Because the mitochondria were autologous (from the patient’s own tissue), no dangerous immune response was observed in this case.
Bottom Line
The first human trial of intra‑ocular mitochondrial injection shows the procedure can be performed safely and may elicit short‑term functional responses, but it does not yet prove that vision can be restored. Further research with controlled, repeated dosing is essential to determine whether this approach can become a viable treatment for vision‑threatening retinal diseases.
Reporting based on: original source.
Comments
Post a Comment